Semaglutide (Ozempic/Wegovy)Deep Dive

Semaglutide is a once-weekly GLP-1 receptor agonist — approved as Ozempic for type 2 diabetes, Wegovy for obesity, and Rybelsus as a daily oral tablet — with the deepest clinical data in the incretin class. The SELECT trial followed 17,604 adults with obesity and established cardiovascular disease for roughly four years on 2.4 mg weekly and delivered a 20% reduction in major cardiac events versus placebo⁵. FLOW showed kidney-outcome benefit in type 2 diabetes with chronic kidney disease at 1.0 mg weekly. ESSENCE produced 62.9% MASH histologic resolution at 2.4 mg vs 34.1% placebo at 72 weeks⁹. And STEP-2 directly compared 1.0 mg with 2.4 mg, which makes semaglutide's stop-short question better measured than most dose decisions in the class.

What the ~4-year SELECT exposure establishes is a safety record with no peer in the class: no unexpected signals at 2.4 mg weekly over chronic duration, across a population larger than any tirzepatide or retatrutide cohort combined. GI side effects scale with dose as they do in every GLP-1, and gallbladder risk is elevated versus placebo (2.6× cholelithiasis odds⁸) — those are the dose-limiting realities. What semaglutide does NOT have is long-term data above 2.4 mg weekly; every trial capped there, and compounded vials at 10, 15, or 30 mg are containers for sub-2.4 mg weekly dosing, not a license to exceed the safety envelope.

The load-bearing dose decision past initial titration is stop-short — and semaglutide's evidence for it is uniquely direct. In STEP-2, 1.0 mg weekly produced ~7.0% weight loss vs 2.4 mg's ~9.6% in T2D+obesity, meaning 1.0 mg retains ~73% of the 2.4 mg weight-loss effect at a fraction of the GI burden. That is a randomized head-to-head dose comparison, not an inference. What's also distinctive is that body weight measurably shifts drug exposure — a 55 kg patient at a given dose has ~40% higher plasma exposure than an 85 kg reference; a 127 kg patient has ~27% lower. This is the only GLP-1 where that's true, and it rarely surfaces in clinical discussion despite directly affecting who responds to which dose.

Comparing options? Try the GLP-1 Comparison tool — or explore deep dives on Tirzepatide (Mounjaro/Zepbound), Retatrutide, and Oral GLP-1s (Rybelsus/Orfoglipron).

What Semaglutide Is

Semaglutide is a modified version of the body's own GLP‑1 (glucagon‑like peptide‑1). A fatty‑acid side chain lets it bind to albumin in the bloodstream, extending its half‑life so one injection covers roughly a week.

GLP‑1 is normally released after you eat. It signals to the brain that food has arrived, slows stomach emptying, and coordinates insulin and glucagon for smooth glucose handling. Semaglutide amplifies and prolongs this signal.

Available forms:

• Once‑weekly injection (Ozempic for diabetes, Wegovy for obesity)
• Daily oral tablet (Rybelsus) using an absorption enhancer to cross the stomach lining — see the complete oral GLP-1 guide for the latest on Wegovy pill and orforglipron

Same mechanism, different delivery.

How Semaglutide Works

As a pure GLP-1 agonist at full native potency (1×), semaglutide works mainly through appetite, fullness, gastric slowing, and glucose coordination. This is effective but has two consequences. First, GI side effects (nausea, vomiting) are common because the same pathway that improves satiety also slows the gut. Second, semaglutide does not have tirzepatide's GIP signal into fat tissue, so its non-diabetic obesity DXA readout is less fat-selective: about 62:38 fat:lean, versus tirzepatide's ~75:25.

Appetite and fullness

At receptors in the brainstem and hypothalamus, semaglutide:

• Quiets hunger and food‑seeking signals
• Increases fullness from a given meal
• Reduces intrusive thoughts about food

Meals feel smaller but more satisfying. Eating less becomes easier without constant deprivation.

Gastric emptying

Semaglutide slows gastric emptying so food leaves the stomach more gradually:

• You feel full longer after eating
• Glucose enters the bloodstream smoothly rather than spiking

For diabetes, this reduces post‑meal glucose excursions. For weight loss, it means more stable energy and fewer "sugar crash" impulses to snack.

Insulin and metabolic effects

At the pancreas and liver, GLP‑1 signalling:

• Increases insulin release when glucose is high
• Reduces glucagon (less liver‑driven sugar output)
• Backs off when glucose is normal, reducing hypoglycaemia risk

Semaglutide also improves insulin sensitivity and helps break the metabolic stall common in insulin‑resistant states.

What the Trials Measured

The direct dose-comparison trial: STEP-2

Study: STEP-2 | Population: BMI ≥27 + T2D | Duration: 68 weeks | Doses: 1.0 mg vs 2.4 mg vs placebo

STEP-2 is what makes semaglutide's stop-short argument uniquely strong in the GLP-1 class: it is the only trial in the family where 1.0 mg and 2.4 mg were directly compared for weight loss in a randomized head-to-head.³

1.0 mg weekly holds ~73% of the 2.4 mg effect. The 1.0 → 2.4 mg step adds roughly 2.6 percentage points of additional weight loss. Whether that last 27% of effect is worth the step up depends on the GI cost, which scales with dose, and the specific goal (weight loss vs cardiovascular protection vs glycemic control). Not every user needs the top of the ladder.

The non-diabetic anchor: STEP-1

Study: STEP-1 | Population: Non-diabetic obesity | Duration: 68 weeks | Dose: 2.4 mg

At the full Wegovy 2.4 mg dose, STEP-1 delivered ~15% mean weight loss over 68 weeks in non-diabetic obesity.¹ About half of participants reached 15% or more; a third reached 20% or more. STEP-1 did not include a 1.0 mg arm, so the STEP-2 73%-retention finding is measured in T2D+obesity. It can guide the stop-short discussion, but it is not a direct non-diabetic obesity dose comparison.

The longest duration: STEP-5 and SELECT

Study: STEP-5 | Duration: 104 weeks | Dose: 2.4 mg weekly. Extended the STEP-1 trajectory to 2 years and confirmed durable weight-loss maintenance at the top dose.

Study: SELECT | Duration: ~4 years | Dose: 2.4 mg weekly | n=17,604. Primary endpoint was cardiovascular outcomes, not weight; but the safety dataset from this trial is the largest and longest for any GLP-1 in either class. No unexpected signals emerged over chronic exposure — semaglutide is the best-characterized incretin in this comparison.

Study: FLOW | Duration: 3.4-year median follow-up | Dose: 1.0 mg weekly | n=3,533. Primary endpoint was kidney outcomes in T2D + CKD, not obesity. This matters because semaglutide's evidence shelf is not just weight loss; it includes hard renal outcomes in the population where kidney risk is already present.

The T2D dose-comparison for glycemic control: SUSTAIN-FORTE

Study: SUSTAIN-FORTE | Population: T2D | Duration: 40 weeks | Doses: 1.0 mg vs 2.0 mg

The second direct dose comparison: 1.0 mg weekly produced ~1.9% HbA1c reduction; 2.0 mg produced ~2.1%. The 1.0 → 2.0 mg step added ~0.2 percentage points of glycemic benefit — measurable but incremental, which is what made Ozempic 2.0 mg a label addition rather than a replacement for 1.0 mg.¹² For T2D patients well-controlled at 1.0 mg, staying there is a defensible clinical position; the 2.0 mg step is for patients who need more glycemic reduction and accept a larger GI burden for it.

Trajectory at any maintenance dose

• Early months: titration and adaptation at 0.25–0.5 mg
• Months 3–6: weight drops faster as maintenance doses are reached and steady-state plasma levels stabilize (semaglutide's ~7-day half-life¹⁰ stabilizes at any new dose within 4–5 weeks)
• Months 6–12+: loss continues but slows as metabolism stabilizes at the new set point

These are trial averages with structured support, not individual guarantees.

Body composition and lean mass

Study: STEP-1 DXA substudy | Population: Non-diabetic obesity | Duration: 68 weeks

DXA data show semaglutide produces a fat:lean ratio of approximately 62:38² — meaning a little under 40% of the lost mass is lean mass, not fat. Someone losing 30 pounds might lose roughly 11 pounds of lean tissue without training and nutrition support.

This ratio fits semaglutide's receptor profile. GLP-1 lowers intake and improves glucose handling, but it does not directly turn on fat-cell fuel burning the way GIP-forward drugs can. Tirzepatide, which adds GIP receptor agonism, produced about 75:25 in the matched non-diabetic obesity DXA anchor. That comparison is cross-trial, not a direct SURMOUNT-5 body-composition endpoint.

In type 2 diabetes the gap may narrow or disappear. The head-to-head Clamp Study (28 weeks, T2D) showed semaglutide at ~86:14 and tirzepatide at ~87:13⁷ — within one percentage point. In that population, tirzepatide still tends to win on absolute fat loss and glucose control, but not necessarily on the fat:lean ratio.

In practical terms:

• Without resistance training and adequate protein, you lose significant lean mass on any GLP-1
• The 62:38 ratio is less fat-selective than tirzepatide in non-diabetic obesity, but the gap is less clear in T2D
• Resistance training and protein (1.0–1.2g per pound of goal weight) can meaningfully shift the ratio regardless of drug

See the GLP-1 muscle preservation guide for evidence-based strategies. For stubborn fat areas once you're already lean, some practitioners add AOD-9604 as a marginal lipolytic adjunct — though its clinical effect is modest (~2% vs placebo in trials).

Head-to-head vs tirzepatide

Study: SURMOUNT-5 | Population: Non-diabetic obesity | Duration: 72 weeks

At maximum tolerated doses, semaglutide produced 13.7% weight loss versus tirzepatide's 20.2%⁶ — 47% less. This is the cleanest available head-to-head comparison. The gap reflects semaglutide's single-receptor limitation: without GIP, it cannot directly engage fat tissue or drive the thermogenic pathways that give tirzepatide its advantage in non-diabetic populations.

Semaglutide's advantage over tirzepatide lies elsewhere — cardiovascular outcomes data and oral availability (see below).

Diabetes trials

In type 2 diabetes, semaglutide at the diabetes dose (1 mg) produces ~6% weight loss over 52 weeks (SUSTAIN-8)⁴ and HbA1c reductions of 1.5–1.9%. At the 2.4 mg obesity dose in diabetic populations (STEP-2), weight loss reaches ~10%.³

The gap between diabetic and non-diabetic results (~6% vs ~15% at comparable doses) follows the same pattern seen with all incretins: T2D blunts the response. But semaglutide's gap is less dramatic than tirzepatide's because semaglutide's primary mechanism is GLP-1, not GIP. In T2D head-to-head comparisons, the body composition ratios converge.

Cardiovascular outcomes: semaglutide's strongest advantage

The SELECT trial (17,604 participants, median 40 months) showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo⁵ in people with obesity and established cardiovascular disease — without requiring diabetes. This is superiority data against placebo in non-diabetic obesity/CVD, which tirzepatide does not have. Tirzepatide's SURPASS-CVOT showed non-inferiority against dulaglutide, an active comparator, which answers a different question.

For people where cardiovascular risk reduction is the primary goal, semaglutide currently has the strongest evidence. For specific lipid effects, see our GLP-1 cholesterol guide.

Semaglutide Dosing

Injected once weekly, subcutaneous. Four ideas carry the dose decision for semaglutide specifically — titration-is-not-therapeutic, stop-short, microdose, and the body-weight-exposure effect.

Titration is titration. 0.25 mg is not a therapeutic dose.

The Wegovy ladder — 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, 4 weeks per step — is calibrated to the drug's pharmacokinetics. Semaglutide's ~7-day half-life¹⁰ stabilizes at any new dose within 4–5 weeks, so each step holds for at least that long before the next loads on top. The 0.25 mg starter is non-therapeutic titration designed to let GI signaling adapt before the first effective dose (0.5 mg). Holding at 0.25 mg indefinitely doesn't deliver the STEP-1 or STEP-2 outcomes — it delivers the GI-adaptation floor.

Starting below 0.25 mg (0.1–0.2 mg) for tolerance-sensitive users is a microdose decision — covered below — not a titration choice.

Stopping short: 0.5 mg and 1.0 mg are defensible maintenance doses, with direct trial evidence

Per STEP-2 above: 1.0 mg weekly retains ~73% of the 2.4 mg weight-loss effect. Per the SUSTAIN program (1–11): 0.5 mg is the well-characterized T2D maintenance dose with chronic safety and efficacy data spanning multiple years. For most users, the effective dose is the lowest one that keeps weight trending and appetite controlled — and for semaglutide specifically, that lives in the 0.5–1.0 mg band with direct trial support, not at the 2.4 mg top.

Independent telehealth protocols converge on the same band — 0.5–1.0 mg as the common stop-short destination for patients prioritizing tolerability, and 0.25 → 0.5 → 1.0 mg as the T2D maintenance ladder. That convergence across independent providers is calibration on the STEP-2 finding rather than additional evidence: the dose-response shape is already measured, and real-world clinical practice matching it raises confidence that the shape holds in populations broader than STEP-2's specific T2D+obesity enrollment.

The exception is cardiovascular protection: the 20% MACE reduction in SELECT was measured at 2.4 mg. Dropping below that dose for the cardiovascular indication is extrapolation, not measured.

Microdose (0.1–0.25 mg) — what the evidence actually says

The Phase 2 obesity dose-finding trial (NCT02453711) tested 0.05 mg/day SC over 52 weeks — which translates to roughly 0.35 mg/week equivalent. That's slightly above the current 0.25 mg/wk label floor and characterizes pharmacologic activity in the starter-dose zone. Below 0.25 mg/wk SC is uncharacterized in weekly-dosing trials, so the microdose case rests on (a) the daily-SC Phase 2 evidence at the low end and (b) the linear dose-proportional PK across 0.25–2.4 mg, which predicts partial-response pharmacology at sub-label exposures. The magnitude of that partial response is not trial-measured, and individual variation at microdose levels is likely higher than at label doses.

The load-bearing uncertainty sits at a specific link: the Phase 2 anchor used daily SC injections, and translating from daily-SC to weekly-SC adds a dose-conversion step on top of the pathway-activator direction (responsive-axis users extracting proportionally more effect than trial populations). Semaglutide's microdose evidence is the thinnest of the three modern GLP-1s for this reason — tirzepatide and retatrutide have direct weekly-SC low arms; semaglutide's low arm is daily-SC, translated. That translation is mechanism-plausible but it is the link that would break first under pressure.

Body weight shifts drug exposure — uniquely for semaglutide

This is the finding that almost never surfaces in clinical practice. Semaglutide is the only GLP-1 where body weight is a clinically relevant dosing covariate:¹¹

A thinner patient (55–70 kg) at 0.5 mg weekly is getting pharmacologic exposure equivalent to 0.7–0.85 mg weekly in the reference-weight population. May respond better, may have more side effects, may reach plateau at a lower label-dose step. A heavier patient (100–130 kg) at 0.5 mg is getting exposure equivalent to 0.35–0.4 mg — and may legitimately need to escalate faster or further to match the pharmacology observed in the pivotal trials.

STEP and SUSTAIN trials enrolled mean BMI ~30–35. The label ladder is calibrated for that range. Users outside it in either direction should expect their effective dose to shift proportionally — lighter users may respond at lower milligrams than the label suggests; heavier users may need to go higher on the ladder to see the same pharmacology. This is not true for tirzepatide.

Oral-SC equivalence — correcting a widespread error

Users switching between Rybelsus (oral) and Ozempic/Wegovy (SC) often encounter the "14 mg oral ≈ 1.0 mg SC" shorthand. This is wrong by roughly 2×. Using actual published steady-state plasma concentrations:¹¹

A patient on 14 mg Rybelsus daily who switches to "1.0 mg equivalent" Ozempic weekly is doubling their semaglutide exposure. Not necessarily dangerous — 1.0 mg is a standard Ozempic dose — but it's not matched exposure, and the GI burden will reflect the step-up.

Oral Rybelsus dosing conditions matter

Rybelsus must be taken ≥30 minutes before food or other drink with no more than 4 oz (120 mL) plain water. Taking with food or <30 min before food reduces exposure markedly; this is the strictest fasting requirement in the incretin class, because the SNAC absorption enhancer works in the gastric epithelium during a narrow window. If that condition isn't met, the oral formulation barely delivers drug.

Dose bands — with evidence grades

Using compounded semaglutide? The semaglutide dosing calculator handles reconstitution, per-injection volumes, microdose titration, and split-frequency schedules. The GLP-1 dosing optimizer splits weekly doses across multiple injections for users with severe GI sensitivity — though the 7-day half-life produces a smoother natural curve than tirz or reta, so splitting is rarely needed.

Real-world evidence — useful, but not randomized dose-response

The formal real-world layer now supports the same general direction as the trials while answering a narrower question. In a 6-month Truveta cohort of non-diabetic obesity, semaglutide users averaged −8.83% adjusted weight loss, and 32.3% were still below 1.7 mg at month 6. That shows real-world semaglutide often works before or below the full Wegovy ceiling, but it does not prove that lower doses equal 2.4 mg over 68 weeks.

The Reddit layer is different. It is useful for symptom language, dose/time heterogeneity, and what users notice during titration — GI symptoms, fatigue, anxiety/insomnia, constipation, and appetite flatness. It is not adjudicated incidence, and it should not replace STEP, SELECT, FLOW, or formal observational RWE.

Semaglutide Side Effects (Ozempic/Wegovy)

Side effects are primarily gastrointestinal, dose-dependent, and worst during the first 4–8 weeks of titration. Most people tolerate semaglutide well once adapted, but understanding what to expect helps you prepare.

Common Side Effects (Affecting 10–40% of Users)

Early satiety is technically the mechanism of action, not a side effect — but it can make hitting protein targets difficult. Plan protein-first meals before fullness sets in.

Less Common Side Effects (1–10% of Users)

• Fatigue and low energy — Usually improves after 2–4 weeks; ensure adequate calories and sleep. See managing GLP-1 fatigue for the full breakdown of why semaglutide causes fatigue and what fixes each type
• Headache — Common in first 1–2 weeks; often related to reduced carbohydrate intake
• Dizziness — Can indicate dehydration; increase fluid intake
• Acid reflux/GERD — Slowed gastric emptying can worsen reflux in some people
• Hair thinning — Associated with rapid weight loss, not semaglutide specifically; usually temporary

Serious Side Effects (Rare but Important)

Gallbladder problems (1–3%): Rapid weight loss increases gallstone risk.⁸ Watch for severe right-sided abdominal pain, especially after meals.

Pancreatitis (<1%): Severe, persistent abdominal pain radiating to the back requires immediate medical attention. Risk is higher with history of pancreatitis or heavy alcohol use.

Thyroid concerns: Rodent studies showed thyroid tumours at high doses. No confirmed human cases, but semaglutide is contraindicated if you or family members have medullary thyroid carcinoma or MEN2 syndrome.

Hypoglycemia: Rare unless combined with insulin or sulfonylureas. Symptoms include shakiness, sweating, confusion.

When to Seek Medical Attention

Contact your healthcare provider immediately if you experience:

• Severe, persistent abdominal pain
• Persistent vomiting (unable to keep fluids down for 24+ hours)
• Signs of pancreatitis (pain radiating to back, fever)
• Symptoms of gallbladder attack (severe right-side pain after eating)
• Signs of allergic reaction (rash, difficulty breathing, swelling)

Managing Side Effects

Most side effects resolve with time and these strategies:

1. Slow titration — Stay at each dose 4+ weeks before increasing
2. Smaller, frequent meals — Avoid large portions that overwhelm slowed digestion
3. Protein first — Eat protein before fullness sets in
4. Avoid trigger foods — High-fat, greasy, or spicy foods worsen nausea
5. Stay hydrated — Dehydration worsens nearly every side effect
6. Time your dose — Some people tolerate injections better in the evening

Screening and follow-up are essential across titration and maintenance.

Semaglutide Cost: Brand-Name vs Compounded

Cost is one of the biggest barriers to semaglutide access. Understanding your options helps you make informed decisions.

Brand-Name Semaglutide Pricing

Without insurance, brand-name semaglutide is expensive:

With insurance, costs vary widely:

• Some plans cover Ozempic for diabetes but not Wegovy for weight loss
• Prior authorization is often required
• Copays can range from $25 to $300+ per month depending on plan

Compounded Semaglutide: What You Need to Know

Compounded semaglutide is semaglutide prepared by compounding pharmacies rather than the original manufacturer. It became popular due to:

• Lower cost (often $200–500/month)
• Brand-name supply shortages
• Insurance denials for weight-loss indications

Key differences from brand-name:

Quality considerations:

• Compounding pharmacies are regulated by state boards, not FDA
• Quality varies significantly between pharmacies
• Look for pharmacies that provide certificates of analysis (CoA)
• 503B outsourcing facilities have stricter oversight than 503A pharmacies

What to ask your provider:

• Which pharmacy do you use, and are they 503A or 503B?
• Can you provide a certificate of analysis for this batch?
• How is the semaglutide stored and shipped?
• What is the concentration and how do I dose it correctly?

Which Option Makes Sense?

Brand-name is preferable when:

• Insurance covers it with reasonable copay
• You want FDA-approved product with standardized quality
• You're risk-averse about medication quality
• You prefer the convenience of pre-filled pens

Compounded may make sense when:

• Brand-name is unaffordable or unavailable
• You have a trusted provider who uses a reputable pharmacy
• You're comfortable with vials and syringes
• You understand the trade-offs in regulatory oversight

The bottom line: Both can work, but the choice isn't just about cost. If you use compounded semaglutide, do so through a clinician who takes responsibility for the supply chain and can verify quality. Cutting corners on quality to save money can defeat the purpose of a carefully designed GLP-1 program.

Where Semaglutide Is Evidence-Led

Semaglutide carries claims no other GLP-1 currently does. These are the places where its evidence is strongest:

• Cardiovascular protection (SELECT, n=17,604, ~4 years). 20% reduction in major adverse cardiac events vs placebo in adults with obesity and established CVD.⁵ The only GLP-1 with placebo-beaten CV outcomes in non-diabetics. Tirzepatide's SURPASS-CVOT showed non-inferiority against an active comparator (dulaglutide), which is a different evidentiary standard.
• MASH histologic resolution (ESSENCE, Phase 3). 62.9% MASH resolution at 2.4 mg vs 34.1% placebo at 72 weeks⁹ — the first positive histologic MASH endpoint for any incretin.
• Direct head-to-head dose-comparison evidence. STEP-2 (1.0 vs 2.4 mg, 68 weeks in T2D+obesity) and SUSTAIN-FORTE (1.0 vs 2.0 mg, 40 weeks in T2D) are the only GLP-1 trials with direct randomized dose arms. This makes the stop-short decision uniquely evidence-backed for semaglutide.
• Safety-record duration. ~4-year SELECT exposure + 2-year STEP-5 + multi-year SUSTAIN and FLOW programs. No other incretin has comparable chronic-duration characterization.
• Low immunogenicity. Anti-drug antibody incidence is 1–3% (Ozempic 1.0%; Wegovy 2.9%; Rybelsus 0.5%) vs tirzepatide's 51–64%. Clinical impact is silent in both so far; the long-horizon question remains open, but semaglutide has the cleaner antibody profile.
• Only GLP-1 with an oral formulation. Rybelsus delivers approximately 0.5 mg SC-equivalent exposure at 14 mg daily — useful for needle-averse users or travel, with the specific dosing-condition caveat (empty stomach, 30-min wait, no more than 4 oz water).
• Widest insurance coverage and pharmacy availability. Approved since 2017; most payers have coverage pathways for T2D at minimum.

Within the landscape, semaglutide produces smaller absolute weight loss than tirzepatide (~15% vs ~21% at top doses in non-diabetic obesity) and smaller than retatrutide at Phase 3 top doses. That is a real magnitude difference. It is not, however, a summary of what semaglutide IS — it is one axis among several on which the three compounds differ. The audience that arrives at semaglutide is often there for the cardiovascular evidence, the MASH evidence, the oral option, or the well-characterized safety record — for any of those, semaglutide is the evidence-led choice, not a compromise.

Semaglutide is the right tool when cardiovascular risk reduction is the primary goal, MASH or metabolic liver disease is present, the patient needs oral delivery, chronic-exposure safety characterization matters, or long-term immunogenicity is a concern. It is the wrong tool when raw weight-loss magnitude is the only priority and the patient has no specific cardiovascular, hepatic, or immunogenic reason to prefer the most-characterized drug in the class.

FAQ

Related Topics

• Complete GLP-1 Comparison — compare all three GLP-1 drugs
• Tirzepatide Guide — dual-agonist with stronger body-composition data
• Retatrutide Guide — triple-agonist with 28.7% weight loss (Phase 3 topline) and 86% liver-fat reduction in a MASLD subset
• Oral GLP-1 Guide — Wegovy pill vs orforglipron for needle-free options
• GLP-1 Muscle Preservation — protect lean mass during weight loss
• Ask FoxAI — peptide research chat for titration questions and protocol design
• NAD+ Guide — cellular energy support that complements metabolic interventions

References

¹ Wilding JPH, Batterham RL, et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021. STEP 1 (NEJM 2021)

² STEP-1 DXA body-composition substudy. PMC8089287

³ Davies M, Faerch L, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes." Lancet. 2021. STEP 2 (Lancet 2021)

⁴ Pratley RE, et al. "Semaglutide versus dulaglutide in type 2 diabetes." Diabetes Obes Metab. 2020. SUSTAIN-8

⁵ Lincoff AM, Brown-Frandsen K, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." N Engl J Med. 2023. SELECT (NEJM 2023)

⁶ Aronne LJ, et al. "Tirzepatide versus semaglutide for obesity." N Engl J Med. 2025. SURMOUNT-5

⁷ Tirzepatide vs semaglutide body composition in T2D. Clamp study

⁸ GLP-1 receptor agonists and gallbladder/biliary disease risk. JAMA Int Med meta-analysis

⁹ Newsome PN, et al. Semaglutide in Patients with Metabolic Dysfunction-Associated Steatohepatitis. NEJM 2025: ESSENCE (PMID 40305708) — Phase 3 histologic-outcome trial; MASH resolution 62.9% on sema 2.4 mg vs 34.1% placebo at 72 weeks. First positive histologic MASH endpoint for an incretin.

¹⁰ Dhillon S. "Semaglutide: a review in type 2 diabetes and obesity." Drugs. 2021: PMID 33296025. ~7-day terminal half-life (longest in the incretin class); 5–7 weeks of residual drug after the last dose; 4–5 weeks to reach steady state at any new dose.

¹¹ Ozempic FDA label §12.3 (NDA 209637) and Wegovy FDA label §12.3 (NDA 215256), plus Carlsson Petri et al. 2018 Diabetes Ther population PK analysis (n=1,612 T2D from SUSTAIN 1/2/3/6/Japan): Carlsson 2018. Body weight is the only clinically relevant PK covariate — 55 kg patient has +40% exposure vs 85 kg reference; 127 kg patient has −27%. Oral-SC equivalence (14 mg oral QD ≈ 0.5 mg SC QW) derived from Cavg,ss comparison between Rybelsus label §12.3 and Ozempic/Wegovy §12.3.

¹² Frías JP, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in adults with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol. 2021: SUSTAIN-FORTE. Direct head-to-head dose comparison in T2D for HbA1c endpoint; basis for Ozempic 2.0 mg label addition.